Table 1 Characteristics of randomised trials comparing drug eluting stents with bare metal stents.
| Study | Diabetes mellitus | Mean age at baseline (years) | Women (%) | Hypertension (%) | Dyslipidaemia (%) | Smoking (%) | Mean follow up (months) | ||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Angiographic | Clinical | ||||||
| Sirolimus eluting stents | |||||||||
| SIRIUS (2003)4 | 279 | 778 | 62.3 | 29.0 | 68.0 | 74.0 | 20.0 | 8 | 9 |
| E‐SIRIUS (2003)1 | 81 | 271 | 62.3 | 29.3 | 64.0 | 74.0 | 33.0 | 8 | 9 |
| C‐SIRIUS (2004)3 | 24 | 76 | 60.5 | 31.0 | 52.0 | 85.0 | 37.0 | 8 | 9 |
| DIABETES (2005)30 | 160 | 66.6 | 37.5 | 66.3 | 61.3 | 47.5 | 9 | 9 | |
| RAVEL (2002)2 | 44 | 194 | 60.7 | 24.0 | 61.0 | 40.0 | 30.0 | 6 | 12 |
| SES‐SMART (2004)8 | 64 | 193 | 63.6 | 28.4 | 64.7 | 63.0 | 16.3 | 8 | 8 |
| Paclitaxel eluting stents | |||||||||
| TAXUS I (2003)5 | 11 | 49 | 64.9 | 11.4 | 63.9 | 80.3 | 50.8 | 6 | 12 |
| TAXUS II (2003)6, 32, 33 | 76 | 453 | 60.1 | 24.4 | 61.5 | 76.6 | 24.8 | 6 | 24 |
| TAXUS IV (2004)7, 29 | 318 | 996 | 62.5 | 27.9 | 69.8 | 65.3 | 21.8 | 9 | 24 |
| TAXUS VI (2005)31 | 89 | 357 | 62.6 | 23.7 | 57.8 | 71.9 | NA | 9 | 12 |
C‐SIRIUS, Canadian sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; DIABETES, diabetes and sirolimus eluting stent trial; E‐SIRIUS, European sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; NA, not available; RAVEL, randomised study with the sirolimus eluting velocity balloon expandable stent; SES‐SMART, randomised comparison of a sirolimus eluting stent and a standard stent in the prevention of restenosis in small coronary arteries; SIRIUS, sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions.